Back to top
more

Soleno Therapeutics (SLNO)

(Delayed Data from NSDQ)

$37.50 USD

37.50
191,129

+0.35 (0.94%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $37.52 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going

Soleno Therapeutics, Inc. (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength

If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data

Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.

Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.

Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Soleno Therapeutics, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why

Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.

Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA

Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.

KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study

KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.

Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.

Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval

Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.

Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection

Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.

Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma

Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.

Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.

RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug

RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease

Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year

Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.

Here's Why Assertio Holdings (ASRT) Stock is Up This Year

Assertio Holdings' (ASRT) successful execution of its restructuring plan, resulting in significant cost savings, is boosting profits.

Zacks Industry Outlook Highlights Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics

Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics are part of Zacks Industry Outlook article.

Kinjel Shah headshot

4 Small Stocks to Bet on in an Upbeat Drugs Industry

It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.

KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M

KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.

Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates

Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.

Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.